REGN7041 clinical trials

A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in patients with Active Noninfectious Uveitis affecting the Posterior Segment

This study is testing a new medicine, REGN7041, for people with a type of eye inflammation called non-infectious uveitis. It's an early-stage study primarily looking at how safe the medicine is and any side effects it might cause when given to humans for the first time.